Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at UBS Group

Jazz Pharmaceuticals (NASDAQ:JAZZ) was upgraded by equities research analysts at UBS Group from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The firm currently has a $179.00 price objective on the specialty pharmaceutical company’s stock, up from their previous price objective of $145.00. UBS Group’s target price would suggest a potential upside of 28.95% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. Royal Bank of Canada decreased their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Barclays restated an “overweight” rating and issued a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Finally, Needham & Company LLC restated a “buy” rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $189.40.

Jazz Pharmaceuticals Trading Up 1.7 %

JAZZ stock opened at $138.81 on Friday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company’s 50-day simple moving average is $128.14 and its 200 day simple moving average is $120.03. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $148.06. The company has a market capitalization of $8.43 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $144.25, for a total value of $937,625.00. Following the sale, the chief executive officer now directly owns 464,058 shares in the company, valued at approximately $66,940,366.50. This trade represents a 1.38 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,193 shares of company stock worth $3,533,122. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. CWA Asset Management Group LLC bought a new position in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after buying an additional 100,112 shares during the last quarter. Centre Asset Management LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at approximately $9,335,000. Moloney Securities Asset Management LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at approximately $464,000. Finally, Pacer Advisors Inc. raised its holdings in Jazz Pharmaceuticals by 15.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after buying an additional 278,465 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.